Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
Shahid Nimjee, M.D., Ph.D.
Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University
Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
About this Seminar
Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.
You May Also Be Interested In...
-
Home Item
Policies to Reduce Ultra-processed Foods: Lessons From Around the Globe , homeJan. 30, 2026, 11:00 a.m. | Lindsey Smith Taillie, Ph.D., MPH, Associate Professor of Nutrition, Associate Chair of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and Addiction Recovery Research Center
-
Home Item
AI and Agentic AI: Opportunities for How We Work, Care, Discover, and Share , homeFeb. 5, 2026, 5:30 p.m. (Reception at 5 p.m.) | Vivian S. Lee, M.D., Ph.D., M.B.A., Executive Fellow, Harvard Business School; Senior Lecturer, Harvard Medical School; Elected Member, National Academy of Medicine | Maury Strauss Distinguished Public Lecture
-
Home Item
Early Childhood Brain Development and Risk for Schizophrenia , homeFeb. 13, 2026, 11 a.m. | John Gilmore, M.D., Eure Distinguished Professor and Vice Chair for Research, Department of Psychiatry, University of North Carolina School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
Is It What You Eat or When You Eat? Evidence for Time Restricted Eating in Humans , homeFeb. 27, 2026, 11:00 a.m. | Lisa Chow, M.D., Professor of Medicine, Pennock Family Land Grant Chair in Diabetes Research, University of Minnesota | Co-Sponsored by the Fralin Biomedical Research Institute Center for Exercise Medicine Research
-
Home Item
A Nicotine-Focused Regulatory Strategy: The Science , homeMarch 13, 2026, 11:00 a.m. | Dorothy Hatsukami, Ph.D., Professor of Psychiatry and Behavioral Sciences and Forster Family Chair in Cancer Prevention, Masonic Cancer Center, University of Minnesota | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – Roanoke
-
Home Item
From BDNF to Rett Syndrome: Synapses, Networks, and Social Behaviors in Mecp2 Mutant Mice , homeMarch 27, 2026, 11:00 a.m. | Lucas Pozzo-Miller, Ph.D., Mall Family Endowed Professor for Genetic Autism Research, Department of Pediatrics & Human Development, College of Medicine, Michigan State University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research